Acrivon Therapeutics presents Phase 2-ready ACR-525 for eosinophilic esophagitis
ACRV•Acrivon Therapeutics outlined initial development plans for its oral JAK1 inhibitor ACR-525 in eosinophilic esophagitis. Phase 1 studies in healthy volunteers showed dose-proportional pharmacokinetics and no serious adverse events, while preclinical tests found protection against epithelial barrier damage.
1. Development plans and early data
Acrivon Therapeutics outlined plans for initial development of ACR-525, its Phase 2-ready oral selective JAK1 inhibitor, in eosinophilic esophagitis. Phase 1 healthy volunteer studies showed dose-proportional pharmacokinetics with no serious adverse events; the company said the clinical data support once-daily dosing.
2. Preclinical findings and rights
Preclinical testing showed ACR-525 protected against IL-13- and OSM-induced epithelial barrier damage, with broader activity than dupilumab. ACR-525 is wholly owned, with no milestone or royalty obligations; its composition-of-matter protection extends to 2038, with extension opportunities.
